US/EU Inspections MRA: Lessons Learned And Challenges Ahead for FDA
You may also be interested in...
The landmark mutual recognition agreement is now operational between 12 EU member states and the US Food and Drug Administration.
Courts may increasingly find limits on how far Park Doctrine tool can be ‘pushed,’ Sklamberg says in wide-ranging interview with the Pink Sheet. Former US FDA deputy commissioner for global regulatory operations and policy, now with law firm Akin Gump, also shares his views on the US-EU MRA to recognize each other’s inspections and data integrity.
Applications for the accelerated assessment of planned EU marketing applications for two drugs are being considered by the European Medicines Agency.